{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T14:34:25Z","timestamp":1776868465922,"version":"3.51.2"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T00:00:00Z","timestamp":1600992000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.bcp.2020.114231","type":"journal-article","created":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T11:50:38Z","timestamp":1600861838000},"page":"114231","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Maraviroc reactivates HIV with potency similar to that of other latency reversing drugs without inducing toxicity in CD8 T cells"],"prefix":"10.1016","volume":"182","author":[{"given":"Mar\u00eda Rosa","family":"L\u00f3pez-Huertas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Jim\u00e9nez-Tormo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Madrid-Elena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Jes\u00fas","family":"Vivancos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Luna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santiago","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2020.114231_b0005","unstructured":"UNAIDS, Fact sheet 2015 | UNAIDS, Unaids. (2017) 1\u20138. https:\/\/doi.org\/http:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/20150901_FactSheet_2015_en.pdf."},{"key":"10.1016\/j.bcp.2020.114231_b0010","doi-asserted-by":"crossref","first-page":"e349","DOI":"10.1016\/S2352-3018(17)30066-8","article-title":"Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: A collaborative analysis of cohort studies","volume":"4","author":"Trickey","year":"2017","journal-title":"Lancet HIV"},{"key":"10.1016\/j.bcp.2020.114231_b0015","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nm880","article-title":"Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells","volume":"9","author":"Siliciano","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2020.114231_b0020","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nrmicro2223","article-title":"Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs","volume":"7","author":"Coiras","year":"2009","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.bcp.2020.114231_b0025","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/nm.3445","article-title":"HIV-1 persistence in CD4+ T cells with stem cell-like properties","volume":"20","author":"Buzon","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2020.114231_b0030","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/nm.1972","article-title":"HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation","volume":"15","author":"Chomont","year":"2009","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2020.114231_b0035","doi-asserted-by":"crossref","first-page":"785","DOI":"10.2217\/fvl-2016-0093","article-title":"HIV-1 latent reservoir: Size matters","volume":"11","author":"Hodel","year":"2016","journal-title":"Future Virol."},{"key":"10.1016\/j.bcp.2020.114231_b0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003398","article-title":"Rapid quantification of the latent reservoir for HIV-1 Using a Viral outgrowth assay","author":"Laird","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.bcp.2020.114231_b0045","doi-asserted-by":"crossref","first-page":"319","DOI":"10.7326\/M14-1027","article-title":"Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: Report of 2 cases","volume":"161","author":"Henrich","year":"2014","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.bcp.2020.114231_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2013.09.020","article-title":"XReplication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure","volume":"155","author":"Ho","year":"2013","journal-title":"Cell."},{"key":"10.1016\/j.bcp.2020.114231_b0055","doi-asserted-by":"crossref","first-page":"4321","DOI":"10.1182\/blood-2012-11-465625","article-title":"Interleukin-7 promotes HIV persistence during antiretroviral therapy","volume":"121","author":"Vandergeeten","year":"2013","journal-title":"Blood."},{"key":"10.1016\/j.bcp.2020.114231_b0060","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1073\/pnas.1522675113","article-title":"Clonally expanded CD4 + T cells can produce infectious HIV-1 in vivo","volume":"113","author":"Simonetti","year":"2016","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bcp.2020.114231_b0065","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/487439a","article-title":"HIV: Shock and kill","volume":"487","author":"Deeks","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2020.114231_b0070","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.immuni.2012.01.014","article-title":"Stimulation of HIV-1-Specific Cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation","volume":"36","author":"Shan","year":"2012","journal-title":"Immunity."},{"key":"10.1016\/j.bcp.2020.114231_b0075","article-title":"T cell toxicity of HIV latency reversing agents","author":"Zhao","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bcp.2020.114231_b0080","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1186\/s12916-015-0517-y","article-title":"HIV-1 functional cure: Will the dream come true?","volume":"13","author":"Liu","year":"2015","journal-title":"BMC Med."},{"key":"10.1016\/j.bcp.2020.114231_b0085","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1742-4690-10-67","article-title":"HIV-1 transcription and latency: An update","volume":"10","author":"Van Lint","year":"2013","journal-title":"Retrovirology"},{"key":"10.1016\/j.bcp.2020.114231_b0090","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/QAD.0000000000001290","article-title":"Reactivation capacity by latency-reversing agents ex vivo correlates with the size of the HIV-1 reservoir","volume":"31","author":"Darcis","year":"2017","journal-title":"AIDS"},{"key":"10.1016\/j.bcp.2020.114231_b0095","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1172\/JCI80142","article-title":"Ex vivo analysis identifies effective HIV-1 latency \u2013 reversing drug combinations","volume":"125","author":"Laird","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcp.2020.114231_b0100","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1093\/infdis\/jiu155","article-title":"HIV-1 Expression within resting CD4+ T cells after multiple doses of vorinostat","volume":"210","author":"Archin","year":"2014","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.bcp.2020.114231_b0105","doi-asserted-by":"crossref","first-page":"e520","DOI":"10.1016\/S2352-3018(15)00226-X","article-title":"Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study","volume":"2","author":"Elliott","year":"2015","journal-title":"Lancet. HIV."},{"key":"10.1016\/j.bcp.2020.114231_b0110","doi-asserted-by":"crossref","first-page":"e1004473","DOI":"10.1371\/journal.ppat.1004473","article-title":"Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy","volume":"10","author":"Elliott","year":"2014","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.bcp.2020.114231_b0115","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/S2352-3018(14)70014-1","article-title":"Panobinostat, a histone deacetylase inhibitor, for latent virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: A phase 1\/2, single group, clinical trial","volume":"1","author":"Rasmussen","year":"2014","journal-title":"Lancet HIV."},{"key":"10.1016\/j.bcp.2020.114231_b0120","doi-asserted-by":"crossref","first-page":"12731","DOI":"10.1038\/ncomms12731","article-title":"Broad activation of latent HIV-1 in vivo","volume":"7","author":"Barton","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2020.114231_b0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005142","article-title":"The depsipeptide romidepsin reverses HIV-1 Latency In Vivo","volume":"11","author":"S\u00f8gaard","year":"2015","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.bcp.2020.114231_b0130","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/COH.0b013e32835ef089","article-title":"Combined approaches for HIV cure","volume":"8","author":"Margolis","year":"2013","journal-title":"Curr. Opin. HIV AIDS."},{"key":"10.1016\/j.bcp.2020.114231_b0135","first-page":"5447","article-title":"Maraviroc: A review of its use in HIV infection and beyond","volume":"9","author":"Woollard","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.bcp.2020.114231_b0140","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1128\/AAC.49.11.4721-4732.2005","article-title":"Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity","volume":"49","author":"Dorr","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bcp.2020.114231_b0145","doi-asserted-by":"crossref","first-page":"4978","DOI":"10.1074\/jbc.M110.168955","article-title":"New insights into the mechanisms whereby low molecular weight CCR5 ligands inhibit HIV-1 infection","volume":"286","author":"Garcia-Perez","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2020.114231_b0150","doi-asserted-by":"crossref","first-page":"7824","DOI":"10.1128\/JVI.74.17.7824-7833.2000","article-title":"Characterization of chemokine receptor utilization of viruses in the latent reservoir for human immunodeficiency virus type 1","volume":"74","author":"Pierson","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.bcp.2020.114231_b0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0027864","article-title":"Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: Effect on T cells latently infected","volume":"6","author":"Guti\u00e9rrez","year":"2011","journal-title":"PLoS One."},{"key":"10.1016\/j.bcp.2020.114231_b0160","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1742-6405-11-33","article-title":"Failure of combined antiretroviral therapy intensification with maraviroc and raltegravir in chronically HIV-1 infected patients to reduce the viral reservoir: The IntensHIV randomized trial","volume":"11","author":"Lafeuillade","year":"2014","journal-title":"AIDS Res. Ther."},{"key":"10.1016\/j.bcp.2020.114231_b0165","first-page":"ofv138","article-title":"Intensifying antiretroviral therapy with raltegravir and maraviroc during early human immunodeficiency Virus (HIV) Infection Does Not Accelerate HIV Reservoir Reduction., Open Forum","volume":"2","author":"Ostrowski","year":"2015","journal-title":"Infect. Dis."},{"key":"10.1016\/j.bcp.2020.114231_b0170","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01931-17","article-title":"Maraviroc is associated with latent HIV-1 reactivation through NF-\u03baB activation in resting CD4 + T cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy","author":"Madrid-Elena","year":"2018","journal-title":"J. Virol."},{"key":"10.1016\/j.bcp.2020.114231_b0175","unstructured":"M.N.S. Symons J, Wensing AMJ, Drylewicz J, Middel A, Hoepelman AIM, Tesselaar K, Vandekerckhove L, van Lelyveld, Maraviroc Induces HIV Production in RCT and In Vitro, Potentially via the NFkB Pathway, in: Conf. Retroviruses Opportunistic Infect., 2015: p. Abstract Number: 549."},{"key":"10.1016\/j.bcp.2020.114231_b0180","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-02634-y","article-title":"The CCR5-Antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-Agonist Bryostatin-1","volume":"7","author":"L\u00f3pez-Huertas","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2020.114231_b0185","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1182\/blood-2007-06-097907","article-title":"CCR7 ligands CCL19 and CCL21 increase permissiveness of resting memory CD4+ T cells to HIV-1 infection: A novel model of HIV-1 latency","volume":"110","author":"Saleh","year":"2007","journal-title":"Blood."},{"key":"10.1016\/j.bcp.2020.114231_b0190","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/1742-4690-8-80","article-title":"Expression and reactivation of HIV in a chemokine induced model of HIV latency in primary resting CD4+ T cells","volume":"8","author":"Saleh","year":"2011","journal-title":"Retrovirology"},{"key":"10.1016\/j.bcp.2020.114231_b0195","doi-asserted-by":"crossref","first-page":"16934","DOI":"10.1073\/pnas.1002894107","article-title":"Establishment of HIV-1 latency in resting CD4+ T cells depends on chemokine-induced changes in the actin cytoskeleton","volume":"107","author":"Cameron","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bcp.2020.114231_b0200","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/j.celrep.2016.02.022","article-title":"IL-7 Induces SAMHD1 Phosphorylation in CD4+ T Lymphocytes, Improving Early Steps of HIV-1 Life Cycle","volume":"14","author":"Coiras","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.bcp.2020.114231_b0205","doi-asserted-by":"crossref","first-page":"27363","DOI":"10.1074\/jbc.M110.210443","article-title":"Protein kinase Ctheta is a specific target for inhibition of the HIV type 1 replication in CD4+ T lymphocytes","volume":"286","author":"L\u00f3pez-Huertas","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2020.114231_b0210","doi-asserted-by":"crossref","DOI":"10.1038\/nprot.2010.73","article-title":"Ex vivo T cell-based HIV suppression assay to evaluate HIV-specific CD8+T-cell responses","author":"S\u00e1ez-Ciri\u00f3n","year":"2010","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.bcp.2020.114231_b0215","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.jinf.2017.09.004","article-title":"Sequential Vacc-4x and romidepsin during combination antiretroviral therapy (cART): Immune responses to Vacc-4x regions on p24 and changes in HIV reservoirs","volume":"75","author":"Tapia","year":"2017","journal-title":"J. Infect."},{"key":"10.1016\/j.bcp.2020.114231_b0220","doi-asserted-by":"crossref","first-page":"e463","DOI":"10.1016\/S2352-3018(16)30055-8","article-title":"Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): A single-arm, phase 1B\/2A trial","volume":"3","author":"Leth","year":"2016","journal-title":"Lancet HIV."},{"key":"10.1016\/j.bcp.2020.114231_b0225","first-page":"3473","article-title":"Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation","volume":"119","author":"Yang","year":"2009","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcp.2020.114231_b0230","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ymeth.2010.10.002","article-title":"Studies of HIV-1 latency in an ex vivo model that uses primary central memory T cells","volume":"53","author":"Bosque","year":"2011","journal-title":"Methods"},{"key":"10.1016\/j.bcp.2020.114231_b0235","doi-asserted-by":"crossref","first-page":"7552","DOI":"10.1073\/pnas.0802203105","article-title":"Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection","volume":"105","author":"Keele","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bcp.2020.114231_b0240","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003161","article-title":"24 Hours in the Life of HIV-1 in a T Cell Line","volume":"9","author":"Mohammadi","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.bcp.2020.114231_b0245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005545","article-title":"A subset of latency-reversing agents expose HIV-infected resting CD4+T-cells to recognition by cytotoxic T-Lymphocytes","volume":"12","author":"Jones","year":"2016","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.bcp.2020.114231_b0250","first-page":"217","article-title":"The effect of latency reversal agents on primary CD8+ T Cells: Implications for shock and kill strategies for human immunodeficiency virus eradication","volume":"8","author":"Walker-Sperling","year":"2016","journal-title":"EBio Med."},{"key":"10.1016\/j.bcp.2020.114231_b0255","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofw189","article-title":"Ongoing clinical trials of human immunodeficiency virus latency-reversing and immunomodulatory agents","volume":"3","author":"Delagr\u00e8verie","year":"2016","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.bcp.2020.114231_b0260","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1177\/135965350901400514","article-title":"Maraviroc: Pharmacokinetics and drug interactions","volume":"14","author":"Abel","year":"2009","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.bcp.2020.114231_b0265","article-title":"The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell function","volume":"6","author":"Clutton","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2020.114231_b0270","doi-asserted-by":"crossref","first-page":"482","DOI":"10.2174\/157016210793499295","article-title":"Long-term immunovirogical effect and tolerability of a maraviroc-containing regimen in routine clinical practice","volume":"8","author":"Genebat","year":"2010","journal-title":"Curr. HIV Res."},{"key":"10.1016\/j.bcp.2020.114231_b0275","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000332023","article-title":"Responses to switching to maraviroc-based antiretroviral therapy in treated patients with suppressed plasma HIV-1-RNA load","volume":"55","author":"Vitiello","year":"2012","journal-title":"Intervirology."},{"key":"10.1016\/j.bcp.2020.114231_b0280","doi-asserted-by":"crossref","DOI":"10.1586\/eri.12.114","article-title":"The MOTIVATE trials: Maraviroc therapy in antiretroviral treatment-experienced HIV-1-infected patients","volume":"10","author":"Van Lelyveld","year":"2012","journal-title":"Expert Rev. Anti. Infect. Ther."},{"key":"10.1016\/j.bcp.2020.114231_b0285","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1089\/aid.2015.0016","article-title":"The efficacy and safety of maraviroc addition to a stable antiretroviral regimen in subjects with suppressed plasma HIV-RNA is not influenced by age","volume":"31","author":"Blanco","year":"2015","journal-title":"AIDS Res. Hum. Retroviruses."},{"key":"10.1016\/j.bcp.2020.114231_b0290","doi-asserted-by":"crossref","first-page":"5984","DOI":"10.1128\/AAC.01077-15","article-title":"Ex vivo bioactivity and HIV-1 latency reversal by ingenol dibenzoate and panobinostat in resting CD4+ T cells from aviremic patients","volume":"59","author":"Spivak","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bcp.2020.114231_b0295","unstructured":"A.M. J. Symons, S.F.L. van Lelyveld, W. de Spiegelaere, A.M.J. Wensing, J.M. Zerbato, P.M. van Ham, J. Drylewicz, A.I.D. A.I.M. Hoepelman, P.U. Cameron, H.K. Lu, K.T. J.A.M. Borghans, L. Vandekerckhove, S.R. Lewin, M. Nijhuis, The antiretroviral CCR5-inhibitor maraviroc effectively reverses HIV latency by phosphorylation of Nf-\u03baB, in: 22nd Int. Aids Conf., Amsterdam, 2018: p. 346."},{"key":"10.1016\/j.bcp.2020.114231_b0300","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2217\/fvl.09.70","article-title":"Establishment and maintenance of HIV latency: Model systems and opportunities for intervention","volume":"5","author":"Marsden","year":"2010","journal-title":"Future Virol."},{"key":"10.1016\/j.bcp.2020.114231_b0305","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/nm.4156","article-title":"Defective proviruses rapidly accumulate during acute HIV-1 infection","volume":"22","author":"Bruner","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2020.114231_b0310","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.ppat.1003834","article-title":"An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients","volume":"9","author":"Spina","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.bcp.2020.114231_b0315","first-page":"213","article-title":"Supervised disulfiram\u2019s superior effectiveness in alcoholism treatment: Ethical, methodological, and psychological aspects","volume":"52","author":"Brewer","year":"2017","journal-title":"Alcohol Alcohol."},{"key":"10.1016\/j.bcp.2020.114231_b0320","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.2174\/1871520615666160504095040","article-title":"Disulfiram\u2019s anticancer activity: Evidence and mechanisms","volume":"16","author":"Jiao","year":"2016","journal-title":"Anticancer. Agents Med. Chem."},{"key":"10.1016\/j.bcp.2020.114231_b0325","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/cit813","article-title":"A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy","author":"Spivak","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.bcp.2020.114231_b0330","doi-asserted-by":"crossref","DOI":"10.1002\/pros.21247","article-title":"Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth","author":"Lin","year":"2011","journal-title":"Prostate"},{"key":"10.1016\/j.bcp.2020.114231_b0335","doi-asserted-by":"crossref","first-page":"6060","DOI":"10.1128\/JVI.02033-10","article-title":"Disulfiram reactivates Latent HIV-1 in a Bcl-2-Transduced Primary CD4+ T Cell model without inducing global T Cell Activation","volume":"85","author":"Xing","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.bcp.2020.114231_b0340","doi-asserted-by":"crossref","DOI":"10.1097\/QAD.0b013e3283570620","article-title":"Disulfiram reactivates latent HIV-1 expression through depletion of the phosphatase and tensin homolog","volume":"27","author":"Doyon","year":"2013","journal-title":"AIDS"},{"key":"10.1016\/j.bcp.2020.114231_b0345","doi-asserted-by":"crossref","unstructured":"and A.P.R. Md Saha Jamaluddin, Pei-Wen Hu, Yih Jan, Edward B. Siwak, The Broad-Spectrum Histone Deacetylase Inhibitors Vorinostat and Panobinostat Activate Latent HIV in CD4+ T Cells In Part Through Phosphorylation of the T-Loop of the CDK9 Subunit of P-TEFb, AIDS Res. Hum. Retroviruses. 32 (2016).","DOI":"10.1089\/aid.2015.0347"},{"key":"10.1016\/j.bcp.2020.114231_b0350","article-title":"HDAC inhibitors enhance T-cell chemokine expression and augment response to PD-1 immunotherapy in lung adenocarcinoma","author":"Zheng","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2020.114231_b0355","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005063","article-title":"An in-depth comparison of latency-reversing agent combinations in various in vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to potently reactivate viral gene expression","volume":"11","author":"Darcis","year":"2015","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.bcp.2020.114231_b0360","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/nm.3489","article-title":"New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo","volume":"20","author":"Bullen","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2020.114231_b0365","article-title":"Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy","author":"Archin","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2020.114231_b0370","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2016.00356","article-title":"HIV latency-reversing agents have diverse effects on natural killer cell function","volume":"7","author":"Garrido","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2020.114231_b0375","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004287","article-title":"Histone deacetylase inhibitors impair the elimination of hiv-infected cells by cytotoxic t-lymphocytes","volume":"10","author":"Jones","year":"2014","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.bcp.2020.114231_b0380","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/infdis\/jiv022","article-title":"Expanded cytotoxic T-cell lymphocytes target the latent HIV reservoir, in","author":"Sung","year":"2015","journal-title":"J. Infect. Dis."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295220304676?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295220304676?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T15:13:03Z","timestamp":1762096383000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295220304676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":76,"alternative-id":["S0006295220304676"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2020.114231","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Maraviroc reactivates HIV with potency similar to that of other latency reversing drugs without inducing toxicity in CD8 T cells","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2020.114231","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"114231"}}